FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:2817-2826 December 30, 2004 Number 27 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor–positive tumors is poorly defined by clinical and histopathological measures.

Methods We tested whether the results of a reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay of 21 prospectively selected genes in paraffin-embedded tumor tissue would correlate with the likelihood of distant recurrence in patients with node-negative, tamoxifen-treated breast cancer who were enrolled in the National Surgical Adjuvant Breast and Bowel Project clinical trial B-14. The levels of expression of 16 cancer-related genes and 5 reference genes were used in a prospectively defined algorithm to calculate a recurrence score and to determine a risk group (low, intermediate, or high) for each patient.

Results Adequate RT-PCR profiles were obtained in 668 of 675 tumor blocks. The proportions of patients categorized as having a low, intermediate, or high risk by the RT-PCR assay were 51, 22, and 27 percent, respectively. The Kaplan–Meier estimates of the rates of distant recurrence at 10 years in the low-risk, intermediate-risk, and high-risk groups were 6.8 percent (95 percent confidence interval, 4.0 to 9.6), 14.3 percent (95 percent confidence interval, 8.3 to 20.3), and 30.5 percent (95 percent confidence interval, 23.6 to 37.4). The rate in the low-risk group was significantly lower than that in the high-risk group (P<0.001). In a multivariate Cox model, the recurrence score provided significant predictive power that was independent of age and tumor size (P<0.001). The recurrence score was also predictive of overall survival (P<0.001) and could be used as a continuous function to predict distant recurrence in individual patients.

Conclusions The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor–positive breast cancer.

Source Information

From the Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh (S.P., G.T., C.K., T.P., W.H., E.R.F., D.L.W., J.B., N.W.); Genomic Health, Redwood City, Calif. (S.S., J.B., M.C., M.G.W., D.W.); the Department of Statistics, University of Pittsburgh, Pittsburgh (G.T., J.B.); and the University of California, San Francisco, San Francisco (F.L.B.).

Address reprint requests to Dr. Paik at the Division of Pathology, NSABP, 4 Allegheny Center, 5th Fl., East Commons Professional Bldg., Pittsburgh, PA 15212, or at spaik.nejm{at}nsabp.org.

Full Text of this Article

This article has been cited by other articles:

• Rutgers, E. J.T., Pusztai, L., Bernards, R. (2008). Are Short-Term or Long-Term Recurrence Rates More Important in Breast Cancer Screening?. ANN INTERN MED 149: 357-357 [Full Text]  
• Goldstein, L. J., Gray, R., Badve, S., Childs, B. H., Yoshizawa, C., Rowley, S., Shak, S., Baehner, F. L., Ravdin, P. M., Davidson, N. E., Sledge, G. W. Jr, Perez, E. A., Shulman, L. N., Martino, S., Sparano, J. A. (2008). Prognostic Utility of the 21-Gene Assay in Hormone Receptor-Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features. JCO 26: 4063-4071 [Abstract] [Full Text]  
• Paik, S., Tang, G., Fumagalli, D. (2008). An Ideal Prognostic Test for Estrogen Receptor-Positive Breast Cancer?. JCO 26: 4058-4059 [Full Text]  
• Jeruss, J. S., Mittendorf, E. A., Tucker, S. L., Gonzalez-Angulo, A. M., Buchholz, T. A., Sahin, A. A., Cormier, J. N., Buzdar, A. U., Hortobagyi, G. N., Hunt, K. K. (2008). Staging of Breast Cancer in the Neoadjuvant Setting. Cancer Res. 68: 6477-6481 [Abstract] [Full Text]  
• Desmedt, C., Haibe-Kains, B., Wirapati, P., Buyse, M., Larsimont, D., Bontempi, G., Delorenzi, M., Piccart, M., Sotiriou, C. (2008). Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes. Clin. Cancer Res. 14: 5158-5165 [Abstract] [Full Text]  
• John, T., Black, M. A., Toro, T. T., Leader, D., Gedye, C. A., Davis, I. D., Guilford, P. J., Cebon, J. S. (2008). Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma. Clin. Cancer Res. 14: 5173-5180 [Abstract] [Full Text]  
• Hershman, D. L., Neugut, A. I. (2008). Anthracycline Cardiotoxicity: One Size Does Not Fit All!. JNCI J Natl Cancer Inst 100: 1046-1047 [Full Text]  
• Fung, E. T, Wilson, A. M, Zhang, F., Harris, N., Edwards, K. A, Olin, J. W, Cooke, J. P (2008). A biomarker panel for peripheral arterial disease. Vasc Med 13: 217-224 [Abstract]  
• Skrzypski, M., Jassem, E., Taron, M., Sanchez, J. J., Mendez, P., Rzyman, W., Gulida, G., Raz, D., Jablons, D., Provencio, M., Massuti, B., Chaib, I., Perez-Roca, L., Jassem, J., Rosell, R. (2008). Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung. Clin. Cancer Res. 14: 4794-4799 [Abstract] [Full Text]  
• Somlo, G., Chu, P., Frankel, P., Ye, W., Groshen, S., Doroshow, J. H., Danenberg, K., Danenberg, P. (2008). Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome. Ann Oncol 0: mdn402v1-mdn402 [Abstract] [Full Text]  
• Turner, N. C, Jones, A. L (2008). Management of breast cancer--Part II. BMJ 337: a540-a540 [Full Text]  
• Peppercorn, J., Partridge, A. H. (2008). Breast Cancer in Young Women: A New Color or a Different Shade of Pink?. JCO 26: 3303-3305 [Full Text]  
• Anders, C. K., Hsu, D. S., Broadwater, G., Acharya, C. R., Foekens, J. A., Zhang, Y., Wang, Y., Marcom, P. K., Marks, J. R., Febbo, P. G., Nevins, J. R., Potti, A., Blackwell, K. L. (2008). Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression. JCO 26: 3324-3330 [Abstract] [Full Text]  
• Sierra, J. R., Corso, S., Caione, L., Cepero, V., Conrotto, P., Cignetti, A., Piacibello, W., Kumanogoh, A., Kikutani, H., Comoglio, P. M., Tamagnone, L., Giordano, S. (2008). Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J. Exp. Med. 205: 1673-1685 [Abstract] [Full Text]  
• Colman, H., Aldape, K. (2008). Molecular Predictors in Glioblastoma: Toward Personalized Therapy. Arch Neurol 65: 877-883 [Abstract] [Full Text]  
• Lee, C. W., Raskett, C. M., Prudovsky, I., Altieri, D. C. (2008). Molecular Dependence of Estrogen Receptor-Negative Breast Cancer on a Notch-Survivin Signaling Axis. Cancer Res. 68: 5273-5281 [Abstract] [Full Text]  
• Schmidt, M., Bohm, D., von Torne, C., Steiner, E., Puhl, A., Pilch, H., Lehr, H.-A., Hengstler, J. G., Kolbl, H., Gehrmann, M. (2008). The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer. Cancer Res. 68: 5405-5413 [Abstract] [Full Text]  
• Grube, B. J., Christy, C. J., Black, D., Martel, M., Harris, L., Weidhaas, J., DiGiovanna, M. P., Chung, G., Abu-Khalaf, M. M., Miller, K. D., Higgins, S. A., Philpotts, L., Tavassoli, F. A., Lannin, D. R. (2008). Breast Sentinel Lymph Node Dissection Before Preoperative Chemotherapy. Arch Surg 143: 692-700 [Abstract] [Full Text]  
• Regan, M. M., Pagani, O., Walley, B., Torrisi, R., Perez, E. A., Francis, P., Fleming, G. F., Price, K. N., Thurlimann, B., Maibach, R., Castiglione-Gertsch, M., Coates, A. S., Goldhirsch, A., Gelber, R. D., for the SOFT/TEXT/PERCHE Steering Committee and th, (2008). Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?. Ann Oncol 19: 1231-1241 [Abstract] [Full Text]  
• Cappelletti, V., Gariboldi, M., De Cecco, L., Toffanin, S., Reid, J. F, Lusa, L., Bajetta, E., Celio, L., Greco, M., Fabbri, A., Pierotti, M. A, Daidone, M. G. (2008). Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer. Endocr Relat Cancer 15: 439-449 [Abstract] [Full Text]  
• Andre, F., Broglio, K., Roche, H., Martin, M., Mackey, J. R., Penault-Llorca, F., Hortobagyi, G. N., Pusztai, L. (2008). Estrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis. JCO 26: 2636-2643 [Abstract] [Full Text]  
• Sauer, G., Schneiderhan-Marra, N., Kazmaier, C., Hutzel, K., Koretz, K., Muche, R., Kreienberg, R., Joos, T., Deissler, H. (2008). Prediction of Nodal Involvement in Breast Cancer Based on Multiparametric Protein Analyses from Preoperative Core Needle Biopsies of the Primary Lesion. Clin. Cancer Res. 14: 3345-3353 [Abstract] [Full Text]  
• Allred, D. C. (2008). Problems and Solutions in the Evaluation of Hormone Receptors in Breast Cancer. JCO 26: 2433-2435 [Full Text]  
• Badve, S. S., Baehner, F. L., Gray, R. P., Childs, B. H., Maddala, T., Liu, M.-L., Rowley, S. C., Shak, S., Perez, E. D., Shulman, L. J., Martino, S., Davidson, N. E., Sledge, G. W., Goldstein, L. J., Sparano, J. A. (2008). Estrogen- and Progesterone-Receptor Status in ECOG 2197: Comparison of Immunohistochemistry by Local and Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory. JCO 26: 2473-2481 [Abstract] [Full Text]  
• Ma, X.-J., Salunga, R., Dahiya, S., Wang, W., Carney, E., Durbecq, V., Harris, A., Goss, P., Sotiriou, C., Erlander, M., Sgroi, D. (2008). A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer. Clin. Cancer Res. 14: 2601-2608 [Abstract] [Full Text]  
• Brennan, D. J., Rexhepaj, E., O'Brien, S. L., McSherry, E., O'Connor, D. P., Fagan, A., Culhane, A. C., Higgins, D. G., Jirstrom, K., Millikan, R. C., Landberg, G., Duffy, M. J., Hewitt, S. M., Gallagher, W. M. (2008). Altered Cytoplasmic-to-Nuclear Ratio of Survivin Is a Prognostic Indicator in Breast Cancer. Clin. Cancer Res. 14: 2681-2689 [Abstract] [Full Text]  
• Ross, J. S., Hatzis, C., Symmans, W. F., Pusztai, L., Hortobagyi, G. N. (2008). Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer. The Oncologist 13: 477-493 [Abstract] [Full Text]  
• Cardoso, F., Saghatchian, M., Thompson, A., Rutgers, E., for the TRANSBIG Consortium Steering Committee, (2008). Inconsistent Criteria Used in American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. JCO 26: 2058-2059 [Full Text]  
• Harris, L. N., Hayes, D. F., Bast, R. C. (2008). In Reply. JCO 26: 2060-2061 [Full Text]  
• Lin, N. U., Winer, E. P. (2008). Optimizing Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: Treating the Right Patients for the Right Length of Time. JCO 26: 1919-1921 [Full Text]  
• Sgroi, D. (2008). Real-Time PCR Biomarker Analysis Using Routine Pathology Specimens. aacredbook 2008: 529-530 [Full Text]  
• Acharya, C. R., Hsu, D. S., Anders, C. K., Anguiano, A., Salter, K. H., Walters, K. S., Redman, R. C., Tuchman, S. A., Moylan, C. A., Mukherjee, S., Barry, W. T., Dressman, H. K., Ginsburg, G. S., Marcom, K. P., Garman, K. S., Lyman, G. H., Nevins, J. R., Potti, A. (2008). Gene Expression Signatures, Clinicopathological Features, and Individualized Therapy in Breast Cancer. JAMA 299: 1574-1587 [Abstract] [Full Text]  
• Park, B.-W., Oh, J.-W., Kim, J.-H., Park, S. H., Kim, K.-S., Kim, J. H., Lee, K. S. (2008). Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol 19: 675-681 [Abstract] [Full Text]  
• Pusztai, L. (2008). Current Status of Prognostic Profiling in Breast Cancer. The Oncologist 13: 350-360 [Abstract] [Full Text]  
• Chanrion, M., Negre, V., Fontaine, H., Salvetat, N., Bibeau, F., Grogan, G. M., Mauriac, L., Katsaros, D., Molina, F., Theillet, C., Darbon, J.-M. (2008). A Gene Expression Signature that Can Predict the Recurrence of Tamoxifen-Treated Primary Breast Cancer. Clin. Cancer Res. 14: 1744-1752 [Abstract] [Full Text]  
• Rudas, M., Lehnert, M., Huynh, A., Jakesz, R., Singer, C., Lax, S., Schippinger, W., Dietze, O., Greil, R., Stiglbauer, W., Kwasny, W., Grill, R., Stierer, M., Gnant, M. F.X., Filipits, M., for the Austrian Breast and Colorectal Cancer Stud, (2008). Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy. Clin. Cancer Res. 14: 1767-1774 [Abstract] [Full Text]  
• Bear, H. D. (2008). Measuring Circulating Tumor Cells As a Surrogate End Point for Adjuvant Therapy of Breast Cancer: What Do They Mean and What Should We Do About Them?. JCO 26: 1195-1197 [Full Text]  
• Yulug, I. G., Gur-Dedeoglu, B. (2008). Functional genomics in translational cancer research: focus on breast cancer. Brief Funct Genomic Proteomic 0: eln009v1-eln009 [Abstract] [Full Text]  
• Marchionni, L., Wilson, R. F., Wolff, A. C., Marinopoulos, S., Parmigiani, G., Bass, E. B., Goodman, S. N. (2008). Systematic Review: Gene Expression Profiling Assays in Early-Stage Breast Cancer. ANN INTERN MED 148: 358-369 [Abstract] [Full Text]  
• Wen, H., Andrejka, L., Ashton, J., Karess, R., Lipsick, J. S. (2008). Epigenetic regulation of gene expression by Drosophila Myb and E2F2-RBF via the Myb-MuvB/dREAM complex. Genes Dev. 22: 601-614 [Abstract] [Full Text]  
• Burden, R. E., Snoddy, P., Buick, R. J., Johnston, J. A., Walker, B., Scott, C. J. (2008). Recombinant cathepsin S propeptide attenuates cell invasion by inhibition of cathepsin L-like proteases in tumor microenvironment. Molecular Cancer Therapeutics 7: 538-547 [Abstract] [Full Text]  
• Sparano, J. A., Paik, S. (2008). Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials. JCO 26: 721-728 [Abstract] [Full Text]  
• Cardoso, F., Van't Veer, L., Rutgers, E., Loi, S., Mook, S., Piccart-Gebhart, M. J. (2008). Clinical Application of the 70-Gene Profile: The MINDACT Trial. JCO 26: 729-735 [Abstract] [Full Text]  
• Ganz, P. A., Hahn, E. E. (2008). Implementing a Survivorship Care Plan for Patients With Breast Cancer. JCO 26: 759-767 [Abstract] [Full Text]  
• Lin, N. U., Winer, E. P. (2008). Advances in Adjuvant Endocrine Therapy for Postmenopausal Women. JCO 26: 798-805 [Abstract] [Full Text]  
• Voduc, D., Cheang, M., Nielsen, T. (2008). GATA-3 Expression in Breast Cancer Has a Strong Association with Estrogen Receptor but Lacks Independent Prognostic Value. Cancer Epidemiol. Biomarkers Prev. 17: 365-373 [Abstract] [Full Text]  
• Laxman, B., Morris, D. S., Yu, J., Siddiqui, J., Cao, J., Mehra, R., Lonigro, R. J., Tsodikov, A., Wei, J. T., Tomlins, S. A., Chinnaiyan, A. M. (2008). A First-Generation Multiplex Biomarker Analysis of Urine for the Early Detection of Prostate Cancer. Cancer Res. 68: 645-649 [Abstract] [Full Text]  
• Finetti, P., Cervera, N., Charafe-Jauffret, E., Chabannon, C., Charpin, C., Chaffanet, M., Jacquemier, J., Viens, P., Birnbaum, D., Bertucci, F. (2008). Sixteen-Kinase Gene Expression Identifies Luminal Breast Cancers with Poor Prognosis. Cancer Res. 68: 767-776 [Abstract] [Full Text]  
• Tan, B. K.T., Tan, L. K., Yu, K., Tan, P. H., Lee, M., Sii, L. H., Wong, C. Y., Ho, G. H., Yeo, A. W.Y., Chow, P. K.H., Koong, H. N., Yong, W. S., Lim, D. T.H., Ooi, L. L.P.J., Soo, K. C., Tan, P. (2008). Clinical Validation of a Customized Multiple Signature Microarray for Breast Cancer. Clin. Cancer Res. 14: 461-469 [Abstract] [Full Text]  
• Dobbe, E., Gurney, K., Kiekow, S., Lafferty, J. S., Kolesar, J. M. (2008). Gene-expression assays: New tools to individualize treatment of early-stage breast cancer. Am J Health Syst Pharm 65: 23-28 [Abstract] [Full Text]  
• Fatouros, M., Baltoyiannis, G., Roukos, D. H. (2008). The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women With BRCA1/2 Mutations. Ann. Surg. Oncol. 15: 21-33 [Abstract] [Full Text]  
• Dobbin, K. K., Zhao, Y., Simon, R. M. (2008). How Large a Training Set is Needed to Develop a Classifier for Microarray Data?. Clin. Cancer Res. 14: 108-114 [Abstract] [Full Text]  
• Hayes, D. F. (2008). Markers for Predicting and Evaluating Response to Therapy for Breast Cancer. Am Soc Clin Oncol Ed Book 2008: 30-34 [Abstract] [Full Text]  
• Hudis, C., Modi, S. (2007). Preoperative Chemotherapy for Breast Cancer: Miracle or Mirage?. JAMA 298: 2665-2667 [Full Text]  
• Lau, S. K., Boutros, P. C., Pintilie, M., Blackhall, F. H., Zhu, C.-Q., Strumpf, D., Johnston, M. R., Darling, G., Keshavjee, S., Waddell, T. K., Liu, N., Lau, D., Penn, L. Z., Shepherd, F. A., Jurisica, I., Der, S. D., Tsao, M.-S. (2007). Three-Gene Prognostic Classifier for Early-Stage Non Small-Cell Lung Cancer. JCO 25: 5562-5569 [Abstract] [Full Text]  
• Schnipper, L. E. (2007). Update in Oncology. ANN INTERN MED 147: 775-782 [Full Text]  
• Schroth, W., Antoniadou, L., Fritz, P., Schwab, M., Muerdter, T., Zanger, U. M., Simon, W., Eichelbaum, M., Brauch, H. (2007). Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes. JCO 25: 5187-5193 [Abstract] [Full Text]  
• Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., Bast, R. C. Jr (2007). American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. JCO 25: 5287-5312 [Abstract] [Full Text]  
• Alexe, G., Dalgin, G. S., Scanfeld, D., Tamayo, P., Mesirov, J. P., DeLisi, C., Harris, L., Barnard, N., Martel, M., Levine, A. J., Ganesan, S., Bhanot, G. (2007). High Expression of Lymphocyte-Associated Genes in Node-Negative HER2+ Breast Cancers Correlates with Lower Recurrence Rates. Cancer Res. 67: 10669-10676 [Abstract] [Full Text]  
• Wang, Z., Dahiya, S., Provencher, H., Muir, B., Carney, E., Coser, K., Shioda, T., Ma, X.-J., Sgroi, D. C. (2007). The Prognostic Biomarkers HOXB13, IL17BR, and CHDH Are Regulated by Estrogen in Breast Cancer. Clin. Cancer Res. 13: 6327-6334 [Abstract] [Full Text]  
• Garman, K. S., Nevins, J. R., Potti, A. (2007). Genomic strategies for personalized cancer therapy. Hum Mol Genet 16: R226-R232 [Abstract] [Full Text]  
• Tozlu-Kara, S, Roux, V, Andrieu, C, Vendrell, J, Vacher, S, Lazar, V, Spyratos, F, Tubiana-Hulin, M, Cohen, P, Dessen, P, Lidereau, R, Bieche, I (2007). Oligonucleotide microarray analysis of estrogen receptor {alpha}-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen. J Mol Endocrinol 39: 305-318 [Abstract] [Full Text]  
• Minna, J. D., Girard, L., Xie, Y. (2007). Tumor mRNA Expression Profiles Predict Responses to Chemotherapy. JCO 25: 4329-4336 [Full Text]  
• Briasoulis, E., Fatouros, M., Roukos, D. H. (2007). Level I Evidence in Support of Perioperative Chemotherapy for Operable Gastric Cancer: Sufficient for Wide Clinical Use?. Ann. Surg. Oncol. 14: 2691-2695 [Full Text]  
• Jiang, J., Sarwar, N., Peston, D., Kulinskaya, E., Shousha, S., Coombes, R. C., Ali, S. (2007). Phosphorylation of Estrogen Receptor-{alpha} at Ser167 Is Indicative of Longer Disease-Free and Overall Survival in Breast Cancer Patients. Clin. Cancer Res. 13: 5769-5776 [Abstract] [Full Text]  
• Thomassen, M., Tan, Q., Eiriksdottir, F., Bak, M., Cold, S., Kruse, T. A. (2007). Comparison of Gene Sets for Expression Profiling: Prediction of Metastasis from Low-Malignant Breast Cancer. Clin. Cancer Res. 13: 5355-5360 [Abstract] [Full Text]  
• Marot, D., Bieche, I., Aumas, C., Esselin, S., Bouquet, C., Vacher, S., Lazennec, G., Perricaudet, M., Kuttenn, F., Lidereau, R., de Roux, N. (2007). High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors. Endocr Relat Cancer 14: 691-702 [Abstract] [Full Text]  
• Abruzzo, L. V., Barron, L. L., Anderson, K., Newman, R. J., Wierda, W. G., O'Brien, S., Ferrajoli, A., Luthra, M., Talwalkar, S., Luthra, R., Jones, D., Keating, M. J., Coombes, K. R. (2007). Identification and Validation of Biomarkers of IgVH Mutation Status in Chronic Lymphocytic Leukemia Using Microfluidics Quantitative Real-Time Polymerase Chain Reaction Technology. J. Mol. Diagn. 9: 546-555 [Abstract] [Full Text]  
• Lee, J. K., Havaleshko, D. M., Cho, H., Weinstein, J. N., Kaldjian, E. P., Karpovich, J., Grimshaw, A., Theodorescu, D. (2007). A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc. Natl. Acad. Sci. USA 104: 13086-13091 [Abstract] [Full Text]  
• Blau, C. A. (2007). Erythropoietin in Cancer: Presumption of Innocence?. Stem Cells 25: 2094-2097 [Abstract] [Full Text]  
• Pollack, J. R. (2007). A Perspective on DNA Microarrays in Pathology Research and Practice. Am. J. Pathol. 171: 375-385 [Abstract] [Full Text]  
• Oratz, R., Paul, D., Cohn, A. L., Sedlacek, S. M. (2007). Impact of a Commercial Reference Laboratory Test Recurrence Score on Decision Making in Early-Stage Breast Cancer. J Oncol Pract 3: 182-186 [Abstract] [Full Text]  
• Lyman, G. H. (2007). Editorial: Gene Expression Profile Assays As an Aid in Treatment Decision Making in Early-Stage Breast Cancer. J Oncol Pract 3: 187-188 [Full Text]  
• Davis, L. M., Harris, C., Tang, L., Doherty, P., Hraber, P., Sakai, Y., Bocklage, T., Doeden, K., Hall, B., Alsobrook, J., Rabinowitz, I., Williams, T. M., Hozier, J. (2007). Amplification Patterns of Three Genomic Regions Predict Distant Recurrence in Breast Carcinoma. J. Mol. Diagn. 9: 327-336 [Abstract] [Full Text]  
• Mullins, M., Perreard, L., Quackenbush, J. F., Gauthier, N., Bayer, S., Ellis, M., Parker, J., Perou, C. M., Szabo, A., Bernard, P. S. (2007). Agreement in Breast Cancer Classification between Microarray and Quantitative Reverse Transcription PCR from Fresh-Frozen and Formalin-Fixed, Paraffin-Embedded Tissues. Clin. Chem. 53: 1273-1279 [Abstract] [Full Text]  
• Henry, N. L., Hayes, D. F. (2007). Can Biology Trump Anatomy? Do All Node-Positive Patients With Breast Cancer Need Chemotherapy?. JCO 25: 2501-2503 [Full Text]  
• Ahn, S. H., Son, B. H., Kim, S. W., Kim, S. I., Jeong, J., Ko, S.-S., Han, W. (2007). Poor Outcome of Hormone Receptor-Positive Breast Cancer at Very Young Age Is Due to Tamoxifen Resistance: Nationwide Survival Data in Korea--A Report From the Korean Breast Cancer Society. JCO 25: 2360-2368 [Abstract] [Full Text]  
• Punglia, R. S., Morrow, M., Winer, E. P., Harris, J. R. (2007). Local Therapy and Survival in Breast Cancer. NEJM 356: 2399-2405 [Full Text]  
• Foukakis, T., Gusnanto, A., Au, A. Y., Hoog, A., Lui, W.-O., Larsson, C., Wallin, G., Zedenius, J. (2007). A PCR-based expression signature of malignancy in follicular thyroid tumors. Endocr Relat Cancer 14: 381-391 [Abstract] [Full Text]  
• O'Dwyer, P. J., Eckhardt, S. G., Haller, D. G., Tepper, J., Ahnen, D., Hamilton, S., Benson, A. B. III, Rothenberg, M., Petrelli, N., Lenz, H.-J., Diasio, R., DuBois, R., Sargent, D., Sloan, J., Johnson, C. D., Comis, R. L., O'Connell, M. J. (2007). Priorities in Colorectal Cancer Research: Recommendations From the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. JCO 25: 2313-2321 [Abstract] [Full Text]  
• Pennati, M., Folini, M., Zaffaroni, N. (2007). Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 28: 1133-1139 [Abstract] [Full Text]  
• Cronin, M., Sangli, C., Liu, M.-L., Pho, M., Dutta, D., Nguyen, A., Jeong, J., Wu, J., Langone, K. C., Watson, D. (2007). Analytical Validation of the Oncotype DX Genomic Diagnostic Test for Recurrence Prognosis and Therapeutic Response Prediction in Node-Negative, Estrogen Receptor-Positive Breast Cancer. Clin. Chem. 53: 1084-1091 [Abstract] [Full Text]  
• Paik, S. (2007). Development and Clinical Utility of a 21-Gene Recurrence Score Prognostic Assay in Patients with Early Breast Cancer Treated with Tamoxifen. The Oncologist 12: 631-635 [Abstract] [Full Text]  
• Ross, J. S., Symmans, W. F., Pusztai, L., Hortobagyi, G. N. (2007). Standardizing Slide-Based Assays in Breast Cancer: Hormone Receptors, HER2, and Sentinel Lymph Nodes. Clin. Cancer Res. 13: 2831-2835 [Abstract] [Full Text]  
• Muss, H. B., Biganzoli, L., Sargent, D. J., Aapro, M. (2007). Adjuvant Therapy in the Elderly: Making the Right Decision. JCO 25: 1870-1875 [Abstract] [Full Text]  
• Crivellari, D., Aapro, M., Leonard, R., von Minckwitz, G., Brain, E., Goldhirsch, A., Veronesi, A., Muss, H. (2007). Breast Cancer in the Elderly. JCO 25: 1882-1890 [Abstract] [Full Text]  
• Bergqvist, J, Ohd, J., Smeds, J, Klaar, S, Isola, J, Nordgren, H, Elmberger, G., Hellborg, H, Bjohle, J, Borg, A-L, Skoog, L, Bergh, J (2007). Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome. Ann Oncol 18: 845-850 [Abstract] [Full Text]  
• Minn, A. J., Gupta, G. P., Padua, D., Bos, P., Nguyen, D. X., Nuyten, D., Kreike, B., Zhang, Y., Wang, Y., Ishwaran, H., Foekens, J. A., van de Vijver, M., Massague, J. (2007). Lung metastasis genes couple breast tumor size and metastatic spread. Proc. Natl. Acad. Sci. USA 104: 6740-6745 [Abstract] [Full Text]  
• Nicolau, M., Tibshirani, R., Borresen-Dale, A.-L., Jeffrey, S. S. (2007). Disease-specific genomic analysis: identifying the signature of pathologic biology. Bioinformatics 23: 957-965 [Abstract] [Full Text]  
• Chabner, B. (2007). Phase II Cancer Trials: Out of Control?. Clin. Cancer Res. 13: 2307-2308 [Full Text]  
• Shak, S., Palmer, G., Baker, J. (2007). Re: Breast Cancer Gene Microarrays Pass Muster. JNCI J Natl Cancer Inst 99: 572-573 [Full Text]  
• Loi, S., Haibe-Kains, B., Desmedt, C., Lallemand, F., Tutt, A. M., Gillet, C., Ellis, P., Harris, A., Bergh, J., Foekens, J. A., Klijn, J. G.M., Larsimont, D., Buyse, M., Bontempi, G., Delorenzi, M., Piccart, M. J., Sotiriou, C. (2007). Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor-Positive Breast Carcinomas Through Genomic Grade. JCO 25: 1239-1246 [Abstract] [Full Text]  
• Ma, Y., Qian, Y., Wei, L., Abraham, J., Shi, X., Castranova, V., Harner, E. J., Flynn, D. C., Guo, L. (2007). Population-Based Molecular Prognosis of Breast Cancer by Transcriptional Profiling. Clin. Cancer Res. 13: 2014-2022 [Abstract] [Full Text]  
• Andre, F., Hatzis, C., Anderson, K., Sotiriou, C., Mazouni, C., Mejia, J., Wang, B., Hortobagyi, G. N., Symmans, W. F., Pusztai, L. (2007). Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor-Positive Breast Cancer. Clin. Cancer Res. 13: 2061-2067 [Abstract] [Full Text]